AstraZeneca, breast cancer
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
Verywell Health on MSN19h
17 Important Resources for Someone Who Has Metastatic Breast CancerIf you have been diagnosed with metastatic breast cancer, resources like support groups, counseling, financial assistance, and online communities can help.
Technology could soon do more than assist doctors. Thanks to advancements in cancer-identifying AI, it could actively save ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
If you have breast cancer, you will have changes in your breast. These may be lumps or changes in the size or color of your breast, or changes in the appearance of your nipples. Breast cancer ...
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Questions about sex and intimacy often go unanswered for people with cancer. It's a glaring problem, especially for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback